Sickle cell gene therapy often comes with a lot of questions. Even when it may be an option, the cost, insurance requirements, and distance from treatment centers can make the process hard to navigate.
Coverage and costs for gene therapy can vary because these treatments are still new, and insurers and states are still working out how to cover them. Here’s what you need to know and where to find support as you explore your options.
Sickle cell gene therapy can cost millions of dollars, but the amount you pay depends on your insurance coverage, medical needs, and where you receive treatment.
Exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) are two gene therapies approved for sickle cell disease in the United States. Casgevy is approved for people ages 2 and older with recurrent pain crises, while Lyfgenia is approved for people ages 12 and older with a history of these events. Vertex Pharmaceuticals makes Casgevy, while Genetix Biotherapeutics makes Lyfgenia.
Their list prices, as reported by the Centers for Medicare & Medicaid Services (CMS), are $3.1 million for Lyfgenia and $2.2 million for Casgevy. However, these upfront costs cover the therapy itself, not necessarily what you’ll pay.
Your out-of-pocket costs will depend on several factors, including:
Even with insurance coverage, you may still have upfront costs and other expenses to manage. Ask your insurer what you’ll pay and which services are covered.
Gene therapy isn’t the only cost to plan for. Other steps in treatment can add their own expenses, including:
If you don’t live near a treatment center, expect travel, lodging, and meal expenses. You may also need time off work, child care, or a caregiver to stay with you.
Fertility preservation is worth discussing too. Conditioning chemotherapy can cause infertility, so ask your care team whether preserving sperm, eggs, or embryos is covered.
Yes, in many cases. But what you pay depends on your insurance plan, eligibility, and state. Coverage can also differ between Medicaid, private insurance, and Medicare.
Although Medicaid covers many people with sickle cell disease (SCD), paying for gene therapy can put added pressure on state Medicaid budgets.
The voluntary Cell and Gene Therapy (CGT) Access Model helps participating states manage the cost of gene therapy. Through this payment model, CMS negotiates agreements with manufacturers based on treatment outcomes.
If the therapy doesn’t meet certain health outcomes, participating state Medicaid programs may receive rebates from the manufacturer. Participating states also receive negotiated discounts on the therapies.
In 2026, 34 Medicaid programs are part of the model, including 32 states, Puerto Rico, and the District of Columbia. But being part of the model doesn’t mean you’ll qualify — you still need to meet its requirements and approval criteria.
The CGT Access Model also provides support for certain services for qualifying Medicaid beneficiaries. Participating manufacturers must pay for specified fertility preservation services, which are provided at no cost to people receiving gene therapy through the model.
Ask your Medicaid program or treatment center which benefits apply to you and what you’ll need to do to access them.
Private insurance and Medicare may also cover gene therapy. But coverage can vary by insurer and treatment program.
If you have private insurance or Medicare, contact your insurer to ask whether Casgevy or Lyfgenia is covered and what you’ll need to pay.
Your insurer may require the following before approving coverage:
If the nearest qualified treatment center is outside your network or state, ask whether your plan covers out-of-network or out-of-state care. You may need approval before traveling.
Even if gene therapy is covered, you may still have deductibles, copays, or coinsurance. Ask what you’ll need to pay out of pocket.
Ask whether related services are billed separately. This can include testing, hospitalization, fertility preservation, travel, or follow-up care.
If your insurer denies coverage, ask for the denial and appeal instructions in writing. Your healthcare team may provide medical records or documentation to support your appeal.
You can start the process by talking to a hematologist. They can assess your eligibility, discuss referrals, and help you understand your insurance requirements.
Here’s what that can involve:
You may need support throughout treatment and long-term follow-up. Ask whether some follow-up care can happen locally to reduce trips to the treatment center.
If gene therapy isn’t an option, ask your sickle cell care team about other treatment options. These include other medications, blood transfusions, a bone marrow transplant, or a clinical trial.
The Sickle Cell Disease Association of America and its member organizations can also connect you with local resources and support.
Eligibility testing takes time. So do insurance approval and choosing a treatment center. Starting early gives you more time to prepare.
Before starting treatment, ask your insurer and sickle cell care team these questions:
Many gene therapy centers have patient navigators or social workers who can help you through the treatment process. Ask to speak with one early on.
Bringing a written list of questions to your first appointment can also help. It’s easy to forget something important once the conversation starts moving quickly.
Get updates directly to your inbox.
Become a member to get even more
This is a member-feature!
Sign up for free to view article comments.
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.